These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 10903737

  • 1. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression.
    Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja ML, Madrenas J.
    J Immunol; 2000 Aug 01; 165(3):1352-6. PubMed ID: 10903737
    [Abstract] [Full Text] [Related]

  • 2. Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation.
    Vandenborre K, Van Gool SW, Kasran A, Ceuppens JL, Boogaerts MA, Vandenberghe P.
    Immunology; 1999 Nov 01; 98(3):413-21. PubMed ID: 10583602
    [Abstract] [Full Text] [Related]

  • 3. Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4.
    Cinek T, Sadra A, Imboden JB.
    J Immunol; 2000 Jan 01; 164(1):5-8. PubMed ID: 10604984
    [Abstract] [Full Text] [Related]

  • 4. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients.
    Pistillo MP, Tazzari PL, Bonifazi F, Bandini G, Kato T, Matsui T, Nishioka K, Conte R, Ferrara GB.
    Transplantation; 2002 Apr 27; 73(8):1295-302. PubMed ID: 11981425
    [Abstract] [Full Text] [Related]

  • 5. Induction of T cell anergy in the absence of CTLA-4/B7 interaction.
    Frauwirth KA, Alegre ML, Thompson CB.
    J Immunol; 2000 Mar 15; 164(6):2987-93. PubMed ID: 10706686
    [Abstract] [Full Text] [Related]

  • 6. Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
    Lazetic S, Leong SR, Chang JC, Ong R, Dawes G, Punnonen J.
    J Biol Chem; 2002 Oct 11; 277(41):38660-8. PubMed ID: 12167647
    [Abstract] [Full Text] [Related]

  • 7. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis.
    Liu Z, Geboes K, Hellings P, Maerten P, Heremans H, Vandenberghe P, Boon L, van Kooten P, Rutgeerts P, Ceuppens JL.
    J Immunol; 2001 Aug 01; 167(3):1830-8. PubMed ID: 11466409
    [Abstract] [Full Text] [Related]

  • 8. The inhibitory function of CTLA-4 does not require its tyrosine phosphorylation.
    Baroja ML, Luxenberg D, Chau T, Ling V, Strathdee CA, Carreno BM, Madrenas J.
    J Immunol; 2000 Jan 01; 164(1):49-55. PubMed ID: 10604992
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement.
    Riley JL, Blair PJ, Musser JT, Abe R, Tezuka K, Tsuji T, June CH.
    J Immunol; 2001 Apr 15; 166(8):4943-8. PubMed ID: 11290772
    [Abstract] [Full Text] [Related]

  • 11. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
    Krummel MF, Allison JP.
    J Exp Med; 1995 Aug 01; 182(2):459-65. PubMed ID: 7543139
    [Abstract] [Full Text] [Related]

  • 12. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.
    Krummel MF, Allison JP.
    J Exp Med; 1996 Jun 01; 183(6):2533-40. PubMed ID: 8676074
    [Abstract] [Full Text] [Related]

  • 13. The expanding world of co-stimulation: the two-signal model revisited.
    Chambers CA.
    Trends Immunol; 2001 Apr 01; 22(4):217-23. PubMed ID: 11274928
    [Abstract] [Full Text] [Related]

  • 14. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes.
    Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, Damle NK.
    J Exp Med; 1992 Dec 01; 176(6):1595-604. PubMed ID: 1334116
    [Abstract] [Full Text] [Related]

  • 15. The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion.
    Rennert P, Furlong K, Jellis C, Greenfield E, Freeman GJ, Ueda Y, Levine B, June CH, Gray GS.
    Int Immunol; 1997 Jun 01; 9(6):805-13. PubMed ID: 9199963
    [Abstract] [Full Text] [Related]

  • 16. Absence of B7-dependent responses in CD28-deficient mice.
    Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB.
    Immunity; 1994 Sep 01; 1(6):501-8. PubMed ID: 7534617
    [Abstract] [Full Text] [Related]

  • 17. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation.
    Dahlén E, Hedlund G, Dawe K.
    J Immunol; 2000 Mar 01; 164(5):2444-56. PubMed ID: 10679081
    [Abstract] [Full Text] [Related]

  • 18. The role of CTLA-4 in induction and maintenance of peripheral T cell tolerance.
    Eagar TN, Karandikar NJ, Bluestone JA, Miller SD.
    Eur J Immunol; 2002 Apr 01; 32(4):972-81. PubMed ID: 11920563
    [Abstract] [Full Text] [Related]

  • 19. Transplantation and the CD28/CTLA4/B7 pathway.
    Alegre M, Fallarino F, Zhou P, Frauwirth K, Thistlethwaite J, Newell K, Gajewski T, Bluestone J.
    Transplant Proc; 2001 Apr 01; 33(1-2):209-11. PubMed ID: 11266782
    [No Abstract] [Full Text] [Related]

  • 20. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.
    Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK.
    Immunity; 1997 Apr 01; 6(4):411-7. PubMed ID: 9133420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.